DrugCombination product
Human umbilical tissue-derived cells clinical trials
Also written CNTO 2476.
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2007
How studies write it
Studies that test it under each name
Development codes
Studies by the year they started
4 studies that test it; most in 2007 (1)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2010 | 1 |
| 2015 | 1 |
| 2018 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 4 · Other 0
Janssen Research & Development, LLC (2) · Centocor, Inc. (1) · Janssen Pharmaceutical K.K. (1)
Studies
Open first, then newest update. How each study uses human umbilical tissue-derived cells is read from its arms, and is right about nine times in ten.
Testing it · 4
- A Study to Evaluate the Safety and Clinical Response of Subretinal Administration of CNTO 2476 in Participants With Geographic AtrophyCompletedPhase 2Janssen Research & Development, LLCNCT02659098Written as CNTO 2476 3.0 x 10^5 cells
- Efficacy and Safety Study of CNTO 2476 in Participants With Visual Acuity Impairment Associated With Geographic Atrophy (GA) Secondary to Age Related Macular Degeneration (AMD)WithdrawnPhase 2Janssen Pharmaceutical K.K.NCT02895815Written as CNTO 2476 (6.0 * 10^4 cells)
- A Safety Study of CNTO 2476 in Patients With Age-Related Macular DegenerationCompletedPhase 1/2Janssen Research & Development, LLCNCT01226628Written as CNTO 2476
- A Study to Evaluate the Safety of CNTO 2476 in Patients With Advanced Retinitis PigmentosaTerminatedPhase 1Centocor, Inc.NCT00458575Written as CNTO 2476